Brain Ischemia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Blood-brain barrier (BBB) breakdown and inflammatory responses are the major causes of tissue-type plasminogen activator (tPA)-induced hemorrhagic transformation (HT), while high-mobility group box 1 (HMGB1) exacerbates inflammatory damage to BBB during the process of brain ischemia/reperfusion.
|
30139371 |
2018 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.
|
21037505 |
2011 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
|
20123226 |
2010 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
[Thrombolysis in acute ischemic stroke in basic hospitals. four cases reports].
|
20488584 |
2010 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator.
|
20536612 |
2010 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke.
|
20212195 |
2010 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Intravenous thrombolysis for acute ischemic stroke: the phase IV data.
|
17903870 |
2007 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
The Interventional Management of Stroke (IMS) II Study.
|
17525387 |
2007 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
[Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France].
|
17086147 |
2006 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.
|
16809570 |
2006 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
|
16126134 |
2005 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
|
15087567 |
2004 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
|
15017018 |
2004 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
|
14986460 |
2004 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Predicting outcome in ischemic stroke: external validation of predictive risk models.
|
12511774 |
2003 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
|
11940547 |
2002 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
|
12221155 |
2002 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
|
11108748 |
2000 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Candidates for thrombolytic treatment in acute ischaemic stroke--where are our patients in Hong Kong?
|
10572812 |
1999 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
|
9566367 |
1998 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.
|
9633741 |
1998 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
|
9400355 |
1997 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
|
9479658 |
1997 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
|
9259745 |
1997 |
Brain Ischemia
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Tissue plasminogen activator for acute ischemic stroke.
|
7477192 |
1995 |